The fracture risk is positivelyĬorrelated with the daily and cumulative glucocorticoid dose in Is associated with bone loss and fractures as the major adverseĮvents ( 4– 6). However, continuous oral steroid therapy for 3–6 months or longer Steroids are widely used to inhibit inflammation inĪ variety of immune-mediated diseases, including systemic lupus In conclusion, treatment with ALN together with CalD significantly elevated the BMD at three skeletal sites, and inhibited urinary Ca excretion and the activity of bone resorption markers in patients with ITP.

Compared with the baseline levels or CalD treatment alone, ALN together with CalD treatment markedly reduced urinary Ca excretion and the serum levels of the bone resorption markers tartrate resistant acid phosphatase 5b and C‑terminal telopeptides of type 1 collagen, at 9 months. Compared with CalD treatment alone, CalD combined with ALN significantly elevated the BMD at the three skeletal sites at 9 months. The results indicated that the BMD of the lumbar vertebrae (L1‑L4), femoral neck and total hip was significantly increased after ALN + CalD treatment for at 6 and 9 months compared with the baseline. The primary outcomes were bone mineral density (BMD) in the lumbar vertebrae (L1‑L4), femoral neck and total hip, as well as bone metabolism markers. The patients received CalD or CalD + ALN treatment for 9 months. A total of 40 ITP patients with steroid treatment were randomized into a placebo group and an ALN (10 mg/day) + CalD group (n=20). The present study was performed to determine whether ALN reduces bone loss in ITP patients. However, the skeletal protective effect of alendronate (ALN) in ITP patients has been rarely reported. Anti‑osteoporotic medications are applied as a therapeutic strategy to prevent bone deterioration in ITP patients. Bone loss is a prominent complication in immunologic thrombocytopenic purpura (ITP) patients with steroid treatment.

Download caltrate d